PL1694354T3 - Sposób zapobiegania i leczenia cukrzycy za pomocą neurturyny - Google Patents

Sposób zapobiegania i leczenia cukrzycy za pomocą neurturyny

Info

Publication number
PL1694354T3
PL1694354T3 PL04803341T PL04803341T PL1694354T3 PL 1694354 T3 PL1694354 T3 PL 1694354T3 PL 04803341 T PL04803341 T PL 04803341T PL 04803341 T PL04803341 T PL 04803341T PL 1694354 T3 PL1694354 T3 PL 1694354T3
Authority
PL
Poland
Prior art keywords
preventing
neurturin
treating diabetes
diabetes
administering
Prior art date
Application number
PL04803341T
Other languages
English (en)
Inventor
Matthias Austen
Ulrike Burk
Original Assignee
Develogen Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Develogen Ag filed Critical Develogen Ag
Publication of PL1694354T3 publication Critical patent/PL1694354T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/507—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
PL04803341T 2003-11-27 2004-11-29 Sposób zapobiegania i leczenia cukrzycy za pomocą neurturyny PL1694354T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03027383 2003-11-27
PCT/EP2004/013534 WO2005051415A1 (en) 2003-11-27 2004-11-29 Method for preventing and treating diabetes using neurturin
EP04803341A EP1694354B1 (en) 2003-11-27 2004-11-29 Method for preventing and treating diabetes using neurturin

Publications (1)

Publication Number Publication Date
PL1694354T3 true PL1694354T3 (pl) 2009-12-31

Family

ID=34626383

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04803341T PL1694354T3 (pl) 2003-11-27 2004-11-29 Sposób zapobiegania i leczenia cukrzycy za pomocą neurturyny

Country Status (9)

Country Link
US (4) US20080241106A1 (pl)
EP (1) EP1694354B1 (pl)
JP (5) JP4838724B2 (pl)
AT (1) ATE435026T1 (pl)
DE (1) DE602004021847D1 (pl)
DK (1) DK1694354T3 (pl)
ES (1) ES2329583T3 (pl)
PL (1) PL1694354T3 (pl)
WO (1) WO2005051415A1 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050222070A1 (en) 2002-05-29 2005-10-06 Develogen Aktiengesellschaft Fuer Entwicklungsbiologische Forschung Pancreas-specific proteins
DK1694354T3 (da) 2003-11-27 2009-10-26 Develogen Ag Fremgangsmåde til at forhindre og behandle diabetes ved anvendelse af neurturin
EP1872790A1 (en) * 2006-06-26 2008-01-02 DeveloGen Aktiengesellschaft New formulation for increasing bioavailability of neurturin
US8637459B2 (en) * 2006-11-08 2014-01-28 Emory University Enhancing a population of insulin releasing cells using GFR-A1 agonists
CA2742839A1 (en) 2007-11-05 2009-05-14 Develogen Aktiengesellschaft Novel neurturin conjugates for pharmaceutical use
JP2011057674A (ja) 2009-09-11 2011-03-24 Omnica Gmbh コエンザイムｑ−１０と抗酸化剤とを含む組成物
ES2632431T3 (es) * 2009-10-30 2017-09-13 Ntf Therapeutics, Inc. Moléculas de neurturina mejoradas
US8445432B2 (en) 2009-10-30 2013-05-21 Ntf Therapeutics Inc Neurturin molecules
US9127083B2 (en) 2009-10-30 2015-09-08 Ntf Therapeutics, Inc. Neurturin molecules
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
US9617517B2 (en) 2011-05-02 2017-04-11 National University Corporation Kumamoto University Small chemical compound which promotes induction of differentiation of stem cells into insulin-producing cells and method for inducing differentiation of stem cells into insulin-producing cells using said small chemical compound
EP2771019A4 (en) * 2011-10-26 2015-06-17 Univ Louisville Res Found METHODS AND COMPOSITIONS FOR THE TREATMENT OF DIABETES AND OTHER DEGENERATIVE NEUROENDOCRINE DISEASES OR DISORDERS
EP2872622A1 (en) * 2012-06-28 2015-05-20 Instituto de Medicina Molecular The use of ret agonist molecules for haematopoietic stem cell expansion protocols and transplantation therapy and a ret agonist kit
AU2014225307A1 (en) 2013-03-08 2015-09-24 The Curators Of The University Of Missouri Methods and compositions for the treatment and/or prevention of type 1 diabetes
MX2017007054A (es) 2014-12-03 2018-05-02 Velicept Therapeutics Inc Composiciones y métodos para usar solabegron de liberación modificada para sintomas del tracto urinario inferior.
IL258856B1 (en) 2015-10-23 2024-03-01 Velicept Therapeutics Inc Zwitterion solvegron and its uses
JP6960106B2 (ja) * 2018-01-17 2021-11-05 Toto株式会社 浴槽用枕
AU2020282758A1 (en) * 2019-05-30 2021-12-23 Immunolux International Corp. Use of poxvirus with autologous induced pluripotent stem cells for vaccination and disease therapy
EP4284440A1 (en) * 2021-01-30 2023-12-06 Universitat Autònoma De Barcelona Gene therapy for monogenic diabetes

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739307A (en) 1995-08-28 1998-04-14 Washington University Polynucleotide encoding neurturin neurotrophic factor
US6743628B1 (en) 1995-08-28 2004-06-01 Washington University Method of cell culture using neurturin
CN1250379A (zh) 1997-01-23 2000-04-12 住友制药株式会社 糖尿病治疗剂
DE69832797T2 (de) * 1997-02-18 2006-08-17 Genentech, Inc., South San Francisco Neurturin-rezeptor
US6043221A (en) 1997-07-30 2000-03-28 Amgen Inc. Method for preventing and treating hearing loss using a neuturin protein product
AU778998B2 (en) 1998-09-22 2004-12-23 University Of Maryland At Baltimore Cystine knot growth factor mutants
WO2000018922A2 (en) 1998-10-01 2000-04-06 Incyte Genomics, Inc. Human carbohydrate-associated proteins
WO2001030375A2 (en) 1999-10-29 2001-05-03 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Use of gdnf for treating corneal defects
US20020081590A1 (en) 2000-02-04 2002-06-27 Aeomica, Inc. Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
DE10290025T1 (de) * 2001-04-19 2003-10-09 Develogen Ag Verfahren zur Differenzierung von Stammzellen in Insulin-produzierende Zellen
US20050222070A1 (en) 2002-05-29 2005-10-06 Develogen Aktiengesellschaft Fuer Entwicklungsbiologische Forschung Pancreas-specific proteins
AU2003238178A1 (en) 2002-05-29 2003-12-12 Develogen Aktiengesellschaft Fur Entwicklungsbiologische Forschung Pancreas-specific proteins
WO2004093804A2 (en) 2003-04-18 2004-11-04 Five Prime Therapeutics, Inc. Human polypeptides encoded by polynucleotides and methods of their use
DK1694354T3 (da) 2003-11-27 2009-10-26 Develogen Ag Fremgangsmåde til at forhindre og behandle diabetes ved anvendelse af neurturin
EP1872790A1 (en) 2006-06-26 2008-01-02 DeveloGen Aktiengesellschaft New formulation for increasing bioavailability of neurturin
CA2742839A1 (en) 2007-11-05 2009-05-14 Develogen Aktiengesellschaft Novel neurturin conjugates for pharmaceutical use

Also Published As

Publication number Publication date
US8399408B2 (en) 2013-03-19
WO2005051415A1 (en) 2005-06-09
JP2016000759A (ja) 2016-01-07
EP1694354A1 (en) 2006-08-30
EP1694354B1 (en) 2009-07-01
US20080241106A1 (en) 2008-10-02
DE602004021847D1 (de) 2009-08-13
JP2014074066A (ja) 2014-04-24
JP2012001546A (ja) 2012-01-05
JP2011251986A (ja) 2011-12-15
US8772233B2 (en) 2014-07-08
JP2007512290A (ja) 2007-05-17
DK1694354T3 (da) 2009-10-26
JP5647577B2 (ja) 2015-01-07
ATE435026T1 (de) 2009-07-15
US20130150293A1 (en) 2013-06-13
JP4838724B2 (ja) 2011-12-14
ES2329583T3 (es) 2009-11-27
US20140274897A1 (en) 2014-09-18
US20110256113A1 (en) 2011-10-20

Similar Documents

Publication Publication Date Title
PL1694354T3 (pl) Sposób zapobiegania i leczenia cukrzycy za pomocą neurturyny
WO2003088923A3 (en) Methods of treating ileus
WO2003096983A3 (en) Method of treating dyslipidemic disorders
WO2005086661A3 (en) Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
TW200738270A (en) Method of treating depression using a TNFα antibody
WO2006073973A3 (en) Novel benzylamine derivatives as cetp inhibitors
RS20060320A (en) Substituted indazole-o-glucosides
IL160319A0 (en) Compositions and method of treating diabetes
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
SG130189A1 (en) Substituted indole-o-glucosides
WO2003096977A3 (en) Methods of treating hepatitis
WO2004014352A3 (en) Methods for treating carbonic anhydrase mediated disorders
MY143599A (en) Pyrazole derivatives, compositions containing such compounds and methods of use
WO2005046603A3 (en) Pyridine compounds
BR0114054A (pt) Método para tratar alergias usando pirazóis substituìdos
MX2007002470A (es) Fenilaminotiazoles sustituidos y su uso.
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
WO2003082260A3 (en) Tuberculosis treatment using pleuromutilin derivatives
WO2006042745A3 (de) Chemisch modifizierte iapp - peptidanaloga
AU2016204334A1 (en) Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds
MXPA03010322A (es) PROCEDIMIENTO PARA LA PREPARACIoN DE POLIISOCIANATOS.
AU7918500A (en) Substituted diazepanes
WO2005051331A3 (en) Chaperone-based therapy for niemann-pick disease
WO2006078336A3 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
AU2003215190A1 (en) Methods and compositions for treating aids and hiv-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules.